Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain

Joseph V. Pergolizzi, Mart van de Laar, Richard Langford, Hans Ulrich Mellinghoff, Ignacio Morón Merchante, Srinivas Nalamachu, Joanne O'Brien, Serge Perrot, Robert B. Raffa

Research output: Contribution to journalArticle

Abstract

Pain is the most common reason patients seek medical attention and pain relief has been put forward as an ethical obligation of clinicians and a fundamental human right. However, pain management is challenging because the pathophysiology of pain is complex and not completely understood. Widely used analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen) have been associated with adverse events. Adverse event rates are of concern, especially in long-term treatment or at high doses. Paracetamol and NSAIDs are available by prescription, over the counter, and in combination preparations. Patients may be unaware of the risk associated with high dosages or long-term use of paracetamol and NSAIDs. Clinicians should encourage patients to disclose all medications they take in a "do ask, do tell" approach that includes patient education about the risks and benefits of common pain relievers. The ideal pain reliever would have few risks and enhanced analgesic efficacy. Fixed-dose combination analgesics with two or more agents may offer additive or synergistic benefits to treat the multiple mechanisms of pain. Therefore, pain may be effectively treated while toxicity is reduced due to lower doses. One recent fixed-dose combination analgesic product combines tramadol, a centrally acting weak opioid analgesic, with low-dose paracetamol. Evidence-based guidelines recognize the potential value of combination analgesics in specific situations. The current guideline-based paradigm for pain treatment recommends NSAIDs for ongoing use with analgesics such as opioids to manage flares. However, the treatment model should evolve how to use low-dose combination products to manage pain with occasional use of NSAIDs for flares to avoid long-term and high-dose treatment with these analgesics. A next step in pain management guidelines should be targeted therapy when possible, or low-dose combination therapy or both, to achieve maximal efficacy with minimal toxicity.

Original languageEnglish (US)
Pages (from-to)327-346
Number of pages20
JournalJournal of Pain Research
Volume5
DOIs
StatePublished - 2012

Fingerprint

Tramadol
Acetaminophen
Analgesics
Pain
Anti-Inflammatory Agents
Therapeutics
Guidelines
Pain Management
Pharmaceutical Preparations
Opioid Analgesics
Drug Prescriptions
Patient Education

Keywords

  • Analgesics
  • Combination analgesics
  • Moderate pain
  • NSAIDs
  • Opioids
  • Severe pain
  • Tramadol/paracetamol

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pergolizzi, J. V., van de Laar, M., Langford, R., Mellinghoff, H. U., Merchante, I. M., Nalamachu, S., ... Raffa, R. B. (2012). Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. Journal of Pain Research, 5, 327-346. https://doi.org/10.2147/JPR.S33112

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. / Pergolizzi, Joseph V.; van de Laar, Mart; Langford, Richard; Mellinghoff, Hans Ulrich; Merchante, Ignacio Morón; Nalamachu, Srinivas; O'Brien, Joanne; Perrot, Serge; Raffa, Robert B.

In: Journal of Pain Research, Vol. 5, 2012, p. 327-346.

Research output: Contribution to journalArticle

Pergolizzi, JV, van de Laar, M, Langford, R, Mellinghoff, HU, Merchante, IM, Nalamachu, S, O'Brien, J, Perrot, S & Raffa, RB 2012, 'Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain', Journal of Pain Research, vol. 5, pp. 327-346. https://doi.org/10.2147/JPR.S33112
Pergolizzi JV, van de Laar M, Langford R, Mellinghoff HU, Merchante IM, Nalamachu S et al. Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. Journal of Pain Research. 2012;5:327-346. https://doi.org/10.2147/JPR.S33112
Pergolizzi, Joseph V. ; van de Laar, Mart ; Langford, Richard ; Mellinghoff, Hans Ulrich ; Merchante, Ignacio Morón ; Nalamachu, Srinivas ; O'Brien, Joanne ; Perrot, Serge ; Raffa, Robert B. / Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. In: Journal of Pain Research. 2012 ; Vol. 5. pp. 327-346.
@article{2c317acfa46d4b3aa24443c723470c38,
title = "Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain",
abstract = "Pain is the most common reason patients seek medical attention and pain relief has been put forward as an ethical obligation of clinicians and a fundamental human right. However, pain management is challenging because the pathophysiology of pain is complex and not completely understood. Widely used analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen) have been associated with adverse events. Adverse event rates are of concern, especially in long-term treatment or at high doses. Paracetamol and NSAIDs are available by prescription, over the counter, and in combination preparations. Patients may be unaware of the risk associated with high dosages or long-term use of paracetamol and NSAIDs. Clinicians should encourage patients to disclose all medications they take in a {"}do ask, do tell{"} approach that includes patient education about the risks and benefits of common pain relievers. The ideal pain reliever would have few risks and enhanced analgesic efficacy. Fixed-dose combination analgesics with two or more agents may offer additive or synergistic benefits to treat the multiple mechanisms of pain. Therefore, pain may be effectively treated while toxicity is reduced due to lower doses. One recent fixed-dose combination analgesic product combines tramadol, a centrally acting weak opioid analgesic, with low-dose paracetamol. Evidence-based guidelines recognize the potential value of combination analgesics in specific situations. The current guideline-based paradigm for pain treatment recommends NSAIDs for ongoing use with analgesics such as opioids to manage flares. However, the treatment model should evolve how to use low-dose combination products to manage pain with occasional use of NSAIDs for flares to avoid long-term and high-dose treatment with these analgesics. A next step in pain management guidelines should be targeted therapy when possible, or low-dose combination therapy or both, to achieve maximal efficacy with minimal toxicity.",
keywords = "Analgesics, Combination analgesics, Moderate pain, NSAIDs, Opioids, Severe pain, Tramadol/paracetamol",
author = "Pergolizzi, {Joseph V.} and {van de Laar}, Mart and Richard Langford and Mellinghoff, {Hans Ulrich} and Merchante, {Ignacio Mor{\'o}n} and Srinivas Nalamachu and Joanne O'Brien and Serge Perrot and Raffa, {Robert B.}",
year = "2012",
doi = "10.2147/JPR.S33112",
language = "English (US)",
volume = "5",
pages = "327--346",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain

AU - Pergolizzi, Joseph V.

AU - van de Laar, Mart

AU - Langford, Richard

AU - Mellinghoff, Hans Ulrich

AU - Merchante, Ignacio Morón

AU - Nalamachu, Srinivas

AU - O'Brien, Joanne

AU - Perrot, Serge

AU - Raffa, Robert B.

PY - 2012

Y1 - 2012

N2 - Pain is the most common reason patients seek medical attention and pain relief has been put forward as an ethical obligation of clinicians and a fundamental human right. However, pain management is challenging because the pathophysiology of pain is complex and not completely understood. Widely used analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen) have been associated with adverse events. Adverse event rates are of concern, especially in long-term treatment or at high doses. Paracetamol and NSAIDs are available by prescription, over the counter, and in combination preparations. Patients may be unaware of the risk associated with high dosages or long-term use of paracetamol and NSAIDs. Clinicians should encourage patients to disclose all medications they take in a "do ask, do tell" approach that includes patient education about the risks and benefits of common pain relievers. The ideal pain reliever would have few risks and enhanced analgesic efficacy. Fixed-dose combination analgesics with two or more agents may offer additive or synergistic benefits to treat the multiple mechanisms of pain. Therefore, pain may be effectively treated while toxicity is reduced due to lower doses. One recent fixed-dose combination analgesic product combines tramadol, a centrally acting weak opioid analgesic, with low-dose paracetamol. Evidence-based guidelines recognize the potential value of combination analgesics in specific situations. The current guideline-based paradigm for pain treatment recommends NSAIDs for ongoing use with analgesics such as opioids to manage flares. However, the treatment model should evolve how to use low-dose combination products to manage pain with occasional use of NSAIDs for flares to avoid long-term and high-dose treatment with these analgesics. A next step in pain management guidelines should be targeted therapy when possible, or low-dose combination therapy or both, to achieve maximal efficacy with minimal toxicity.

AB - Pain is the most common reason patients seek medical attention and pain relief has been put forward as an ethical obligation of clinicians and a fundamental human right. However, pain management is challenging because the pathophysiology of pain is complex and not completely understood. Widely used analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen) have been associated with adverse events. Adverse event rates are of concern, especially in long-term treatment or at high doses. Paracetamol and NSAIDs are available by prescription, over the counter, and in combination preparations. Patients may be unaware of the risk associated with high dosages or long-term use of paracetamol and NSAIDs. Clinicians should encourage patients to disclose all medications they take in a "do ask, do tell" approach that includes patient education about the risks and benefits of common pain relievers. The ideal pain reliever would have few risks and enhanced analgesic efficacy. Fixed-dose combination analgesics with two or more agents may offer additive or synergistic benefits to treat the multiple mechanisms of pain. Therefore, pain may be effectively treated while toxicity is reduced due to lower doses. One recent fixed-dose combination analgesic product combines tramadol, a centrally acting weak opioid analgesic, with low-dose paracetamol. Evidence-based guidelines recognize the potential value of combination analgesics in specific situations. The current guideline-based paradigm for pain treatment recommends NSAIDs for ongoing use with analgesics such as opioids to manage flares. However, the treatment model should evolve how to use low-dose combination products to manage pain with occasional use of NSAIDs for flares to avoid long-term and high-dose treatment with these analgesics. A next step in pain management guidelines should be targeted therapy when possible, or low-dose combination therapy or both, to achieve maximal efficacy with minimal toxicity.

KW - Analgesics

KW - Combination analgesics

KW - Moderate pain

KW - NSAIDs

KW - Opioids

KW - Severe pain

KW - Tramadol/paracetamol

UR - http://www.scopus.com/inward/record.url?scp=84874966803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874966803&partnerID=8YFLogxK

U2 - 10.2147/JPR.S33112

DO - 10.2147/JPR.S33112

M3 - Article

C2 - 23055775

AN - SCOPUS:84874966803

VL - 5

SP - 327

EP - 346

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -